Cognitive Diagnostics Market Projected to Reach Unprecedented Growth by 2033

Posted by Ganesh Shinde on May 3rd, 2023

As per Future Market Insights latest industry analysis, the valuation for the global Cognitive Diagnostics market sales is estimated to reach US$ 110.2 Billion in 2023 and is projected to exhibit a CAGR of 8.0% over the forecast period, with an estimated valuation of US$ 238.3 Billion by 2033.

Several causes of brain problems or cognitive disorders include closed head injuries, contact with neurotoxins (toxic substances), genetics, infections, strokes, and tumours. Depending on the area of the brain that is impacted, a person may have a certain form of cognitive problem. Communication issues could result from, for instance, a tumour in the speech cisterns of the brain. In another illustration, a brain infection that affects the motor recentres would cause problems with movement. Ageing is also a factor in the development of cognitive problems.

Cognitive diagnostics increasingly use digital health technologies like wearables and smartphone apps. These tools can monitor a patient's cognitive health and give medical personnel real-time information for more precise diagnosis and management.

The market for cognitive diagnostics is seeing an increase in collaboration and partnerships between academic institutions, technological businesses, and healthcare providers. These partnerships can foster creativity, provide access to technology and techniques for cognitive disorders diagnosis, and hasten the creation of novel treatments for these conditions. For example, in June 2022, Avant Institute, in partnership with COGNIVUE, was awarded a grant by the Davos Alzheimer’s Collaborative to launch an innovative early-detection program for Alzheimer’s disease.

Key Players

• Cognetivity Neurosciences
• Cognivue, Inc.
• Cogstate Ltd.
• Cambridge Cognition Ltd.
• Diadem srl
• CN Diagnostics

Get More Insights@ https://www.futuremarketinsights.com/reports/cognitive-diagnostics-market

Key Market Segments Covered in the Cognitive Diagnostics Industry Research

Diagnosis:

• Brain Imaging Tests
  • Magnetic Resonance Imaging (MRI)
  • Computerized Tomography (CT)
  • Positron Emission Tomography (PET) and PET/CT
• Laboratory Testing
  • Cerebrospinal fluid (CSF)
  • Blood Tests
• Mental Status Testing
  • Mini-Mental State Exam (MMSE)
  • Montreal Cognitive Assessment (MoCA)
• Rapid Home Screening Tests
• Neuropsychological Testing
• Electroencephalogram (EEG)
• Cognitive Function & Behavioral Tests
• Neuropsychiatric Inventory Questionnaire (NPI-Q)

Indication:

• Alzheimer’s disease
• Attention deficit/hyperactivity disorder
• Dementia
• Epilepsy-Related Cognitive Dysfunction
• Mild Cognitive Impairment
• Parkinson’s Disease-related Cognitive Dysfunction
• Stroke-related Cognitive Dysfunction
• Traumatic Brain Injury
• Others

End User:

• Hospitals
• Neurology Clinics
• Cognitive Behavioral Therapy Centers
• Rehabilitation Centers
• Academic and Research Institutes
• Diagnostic Imaging Centers
• Home Care Settings